Low-Flow, Low-Gradient Aortic Stenosis with a Borderline Dobutamine Response

This is low-flow, low-gradient severe aortic stenosis with reduced ejection fraction (classical low-flow low-gradient AS). The criteria are met: aortic valve area ≤1.0 cm² (0.85), mean gradient <40 mmHg (21), LVEF <50% (32%) and stroke volume index ≤35 mL/m² (28). A Doppler velocity index of 0.19 (14/72) is well below the 0.25 threshold and independently supports a severe lesion.

The discordance is physiological, not contradictory. Transaortic gradient is proportional to flow squared, so a failing ventricle that ejects a small stroke volume generates a low gradient even through a severely stenotic orifice. The AVA, by contrast, is derived from flow, so at low flow the calculated area is small; the question is whether the valve is intrinsically severe or merely appears so because it is under-perfused (pseudo-severe AS).

Before accepting the classification, exclude measurement error, which is the commonest cause of an apparently low gradient with a small area:

• LVOT diameter is the single largest source of error because it is squared in the continuity equation - measure 5–10 mm below the annulus, average over several beats, and check that the LVOT VTI and diameter come from the same level.
• Ensure the aortic VTI is a genuine peak from the best window (apical, right parasternal, suprasternal) with correct alignment.
• Consider pressure recovery if the aorta is narrow.

Contractile reserve in this context is conventionally defined as a ≥20% increase in stroke volume index (some laboratories also accept a ≥20% rise in LVEF) during low-dose dobutamine.

Here the stroke volume index rose from 28 to 33 mL/m² - an increase of about 18% - and LVEF from 32% to 38%, about 19%. Both fall just short of the threshold, and the study was truncated by symptoms at 15 µg/kg/min. This is best described as borderline or absent contractile reserve, not a clear positive response, and it is a limited study.

The logic of the test:

• With reserve, flow increases; if the gradient rises above 40 mmHg while the area stays ≤1.0 cm², the valve is truly severe. If the area increases above 1.0–1.1 cm² with only a modest gradient rise, the valve is pseudo-severe and the myopathy is the primary problem.
• Without reserve, flow cannot be increased, so the area cannot be recruited. A negative result does not prove pseudo-severe disease, and the test loses its discriminating power.

So the correct conclusion is: probable true severe AS, but the dobutamine study is non-diagnostic and should not be used to deny intervention.

Aortic valve calcium scoring by non-contrast CT is the best next test when dobutamine is non-diagnostic. Heavy calcification supports true severe stenosis - commonly used thresholds are ≥1,200 Agatston units in women and ≥2,000 in men. A markedly low score argues for pseudo-severe disease and redirects attention to the cardiomyopathy.

Caveats to flag explicitly:

• Moderate mitral regurgitation affects the forward stroke volume that the continuity equation relies on, and can distort both the LVOT VTI and the derived area; the valve area in this situation is less trustworthy than the calcium score and the DVI trend.
• Syncope in this patient may not be due to the valve at all - consider arrhythmia, orthostatic causes and the low-output state; a syncopal episode should not be attributed to AS without review.
• The truncated dobutamine study limits interpretation; if the patient is stable, a repeat with a lower-dose protocol or alternative confirmatory imaging may be preferable to a definitive statement.
• Report the measurements with their known error margins rather than a single decimal, and state the classification with the caveats attached so the multidisciplinary team, not the echo report, makes the decision.